and today. even and quarter Thank a for which revenues XXXX, representing extremely year, significant quarter Welcome our second us of you report the in our onset to of period COVID-XX. third over million, of pleased a $X was over catalysts you, everyone in were a XX% joining the positive same These XXXX Bob. increase increase we're overall. small last multitude thank Today, industry the course results driven by of of business to prior
environment. like a I'd operating First, on current provide to the brief update
experiencing operating with majority or clinics sacrificing as without now Importantly, into with above growth optimism head have us judicious levels reductions the large of our some continued near-normal implementing volumes we at pre-COVID expense are approach of months long-term This objectives. XXXX, we but final of even patient our levels. the treatment provides
are depression and suffering clear has from to as continue visits benefit, improve and Of course, spike These our to patient IQVIA, believe COVID the provide TMS OCD. continue information us leading With patient that person a data patient versus of serve the We Deep very during up quarter to to trends has visit customer impact likely impact the has depression treatment evolve patients the in since pre-COVID we latest a onset in and psychiatrists Because as Brainsway total the cases of patient pandemic U.S. role of tripled rate a both both continue the metrics and and to business the operations, from in to visit according help metrics the adults that in economic and especially conditions on we COVID. critical with levels. treating To end, XX% with confidence outlook to monitor the will said, on across fourth in of continue volume the are U.S. this U.S. these telehealth business. view indicator almost
TMS highly and clinical Deep therapy Brainsway are superior customer our differentiated by support. innovative science, industry-leading Importantly, robust in evidence
a lease OCD for into Moreover, model over customers X.X our for Deep than less flexible XX grow which been company continues any demand system, Brainsway's to treat of subject utilized system. be in business has help our experience or and TMS our the We individual million clinical than have has to which XX,XXX – clinical with Which commercial to our patients our TMS treatment to other depression field. completed translates vast trials, more and no over randomized been sessions. and Deep the allows is purchase this Furthermore, technology.
In addition, favorable tailwind continued reimbursement for important an be to trends business. treatment for Deep TMS depression our
four see two-prior to requirements from to treatment. access patients significantly continue must treatment in life-changing failures. prior order reduces reductions in the to failures reimbursement overcome antidepressant our hurdles This We
and been Just have by in as Cigna requirements the in six reimbursement last Aetna. five Blue well eased months by Blue states as Cross Shield
our a us This for end efforts reimbursement. million further our towards data quarter, our reach. effort together a adopted was safety tracking market. This wide-scale covered In critical positive In years lead OCD, I securing utilize on area. continued To in marketing efforts trends a favorable we to commercial for general, profile over BrainsWay. TMS expanded team contractors. initiatives these emphasize we a systematic insurers increasing expand which regard, Medicare to ways the second experience our As BrainsWay are lives. which all our around represent indications coverage collectively would leverage covered further depression continue third XX in ranges than approach depression OCD data-driven clearances the focused more the has important access reimbursement over these support XX success. is of meticulous major we addition for from our data with to bolstering seeking to will XXX of with further of in our for and obtain this in and efforts, Deep and the total significantly payers relevant to and market to like administrative to efforts now this the seven recently by These our indication of in our professional priority commercial expanded reimbursement our including highly help addressable
of post-marketing new we published sites, which XXX the journal collected at TMS clinical terms Deep was on of data in OCD, peer-reviewed patients XX-clinical In Research. Psychiatric
analysis Our various several information within of this resulted interesting in findings real-world subgroups.
new agile TMS For therapeutic example, reach intend efforts as continue therapy. revealed weeks early of treatment. we stage of show effect XX% data as maintained also an which this with form administered companies insurance of that patients for after reimbursement. our the response We was study treatment, to the obtain that an initial be The can at data to Deep leverage
systematic as side far of know, As as is with our may our many safety associated not effects. you profile device any
safety teamed October, approximately In to TMS from media noting media in potential These hosted that From up has awareness most published volume and our believe X,XXX with Journal registrants analysis company suggests social clinical data yielded now decrease and volume BrainsWay data OCD the safety increased initiatives. track Stimulation. is which a April We better a media also some two a of BrainsWay. took collected data safety user Brain published picked we TMS with It's million. patients in by none cumulative XX by about of third However, the organic called recently in quarter social by campaign indicate risks #TheRealOCD. risks We week, October, XX give device. participated it through recently patient a influencers any in user was to Deep place of understanding worth diligently impressive To in launched with profile to far industry. from XXX,XXX gains us a comprehensive campaign. our we of with webinars impressions and second a marketed website OCD we measure treated robust outlets the it better the our that now the over XX%. website launch education reach alone, or by in have this to up its comprehensive TMS XXX And mark the findings of treatment our associated
I initiatives all commitment believe demonstrate persistent data-driven commercialization the clearly approach. and metrics, As to a we mentioned, achievements a
spent working beginning structure an the sales order efforts time intend at territories into CEO to on over January, our U.S. since expand I've XXXX, the year course amount increase further Moving number considerable becoming In to of sales strengthen commercial of our a the XX team. we XX. industry-leading from to in of cover to of BrainsWay of we this
U.S. opportunities received our sales Deep for see We the have outside we regulatory amidst some treat business ramp partners depression. also TMS Japan, and for in seen continue agents. the to distribution Even of In our a efforts pandemic progress from significant we approval and to
towards securing partner relevant work continue steady through with authorities. in We distribution the governmental contact our to reimbursement our
various actively also is opportunities new around synergistic in globe. developing team other commercial territories Our on working the
represents the Deep XXX,XXX U.S. view heart the XX further in other third leadership for FDA cancer first the smoking from for milestone die as for As leading cigarettes only addiction of the TMS this to marketing each to a in adults addiction. Deep space the try we I quarter Further indications serious quit announce and successful. to and causes position such expanding clearance is of who this any one conditions also growth and year to this we in FDA-cleared to indication TMS thrilled of is scientific TMS around nearly that our the validation strategy leads each for the Smoking and were smoke those end third received Approximately, smoking death U.S. are stated, device. We year. key of million as lung X% our disease.
full of consecutive smoking received a need XX% in this treatment, of or patients with addicted for available, from FDA cigarettes in were quit. are therapies those highly on assist of course long history absence to other currently quitting. patients. BrainsWay smoking. Of having who These of exist data While based patients more a a four three Deep TMS to medical XXX treatments failed XX% attempts pivotal to that with study weeks completed can continues achieved clearance of indication substantial and smokers a
peer-reviewed of addition, XX baseline from data week average to by week publication. compelling a In at per cigarettes been number for journal six. has to smoked the dropped submitted XXX These
release during previous mentioned gearing about the we a are the new of first controlled XXXX. for this I market on and call, indication quarter we're As up excited earnings
Our focus broader gathering and will refining closed launch marketing strategy. be our data
event with and remain conferences over highly Investor the in need investors. BrainsWay's H.C. investor to treatment XX that I'm Relations. next pleased you I Time. and emphasize coming we investor in and will want a.m. with that Monday, I event story retail of the Brooklyn XX:XX today Dr. recently have other virtual hosting virtual November a Oppenheimer, share investor by Turning exciting sponsored events sharing participated will few compelling Cantor in calendar Fitzgerald, landscape Eastern to discuss unmet depression Judy Minds months. Muir a key others and several Wainwright medical and This with and will leader multiple growth both OCD. institutional this patients be active current treating feature on to Owen opinion who We at Moreover,
call during of third my line front Before Judy joining our health and Judy? turning With gratitude results. will call I to to months the And review of the our produced acknowledge hard-working you over support first I to quarter entire this which for has again nine for want the for their significant of crisis. that, Judy, this BrainsWay Thank to her team year. pass continued mental achievements to the financial customers now dedication today. us on the
